Skip to main content
OpenTrials

Clinical trial condition

Synucleinopathies

Explore clinical trials studying Synucleinopathies. Study availability and eligibility vary by location and protocol.

3,496 public trials 645 recruiting studies
Refine in advanced search Browse all conditions

Synucleinopathies trial results

Completed

Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's Disease

NCT00539214

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +6 more
Locations
  • Boehringer Ingelheim Aalen, Germany
  • Boehringer Ingelheim Aarbergen, Germany
  • Boehringer Ingelheim Adendorf, Germany
  • Boehringer Ingelheim Aham, Germany
View all 317 locations
View Trial Details
Completed

A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

NCT00148486

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +6 more
Locations
  • Pivotal Reaserch Centers Peoria, Arizona, United States
  • Boehringer Ingelheim Investigational Site Tucson, Arizona, United States
  • PMDI Fountain Valley, California, United States
  • Boehringer Ingelheim Investigational Site Fresno, California, United States
View all 55 locations
View Trial Details
Completed

A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations

NCT00148512

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +6 more
Locations
  • Krankenhaus d. Barmherzigen Brüder Graz-Eggenberg Graz, Austria
  • Univ.-Klinik für Neurologie Graz, Austria
  • Univ.-Klinik für Neurologie Innsbruck, Austria
  • Landesnervenklinik Wagner Jauregg Linz Linz, Austria
View all 50 locations
View Trial Details
Completed

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

NCT00605683

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +7 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Arizona Neurological Institute Phoenix, Arizona, United States
  • Pacific Neuroscience Medical Group Oxnard, California, United States
  • San Francisco Clinical Research Center San Francisco, California, United States
View all 125 locations
View Trial Details

Related conditions